Home
Categories
Ingredients
Analysis
Manufacturing
Finance
Regulatory
Drug Delivery
Research & Development
Sustainability
Company News
Events
Directory
Search
Close search
Home
Company
Summit plc
Summit plc
Activities:
Manufacturing
Ingredients
Research & Development
Infection Control
Pharmaceutical
X
LinkedIn
Trending Articles
LUNA 3: Rilzabrutinib Phase III immune thrombocytopenia trial meets primary endpoint
Rilzabrutinib met both the primary endpoint of durable platelet response and various secondary endpoints in patients who were refractory to prior therapy
Fasenra for EGPA: addressing unmet needs
Benralizumab could offer patients with EGPA more treatment options, while reducing dependency on oral corticosteroids
Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222
Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the...
Chemistry, manufacturing and control (CMC) as key drivers for drug discovery success
Embracing collaborative strategies not only accelerates drug development programmes but also fosters science-based milestone decisions, mitigates risks and prepares for...
Bristol Myers Squibb and Cellares partner to expand CAR-T manufacturing capabilities
Cellares will optimise and automate select Bristol Myers Squibb CAR-T cell therapies onto its high-throughput manufacturing program, the Cell Shuttle
Upcoming event
Cleanroom Conference UK
22–23 May 2024 | Exhibition | Birmingham, UK
See all
Related Content
Summit appoints Dr David Roblin as Chief Medical Officer
Roblin has been involved in the successful development of a number of important medicines in a range of therapy areas
Research & Development
Wellcome Trust awards Summit £4m to further develop C. Difficile antibiotic
Phase I trial to start by end of the year with results expected in first half of 2013
Research & Development
Summit agrees technology licence with Bristol-Myers Squibb
Summit will receive $100,000 fee for access to its Seglin technology
Manufacturing
Cambridge Major Labs supports Summit antibiotic project
The chemistry outsourcing partner will help develop Summit’s antibiotic for Clostridium difficile
Subscribe now